Siemens Healthineers says sales growth to return next year
Reuters
Published Nov 02, 2020 06:12
Updated Nov 02, 2020 07:20
AMSTERDAM (Reuters) - German health technology company Siemens Healthineers (DE:SHLG) said on Monday it expected sales to rise 5 to 8% in the coming year as efforts to contain the COVID-19 pandemic allow hospitals to resume routine care testing activities.
Comparable sales fell 2% in the fourth quarter of Healthineers' fiscal year 2020, while operating profit was down 20% at 626 million euros (564.22 million pounds), as the care for coronavirus patients significantly limited demand for routine care tests.
The pandemic also increased the costs of the diagnostics division as factories were not used to full capacity while research expenditure on efforts to help fight the disease rose.
Analysts polled by the company on average had expected adjusted earnings before interest and taxes (EBIT) of 644 million euros for the July-September period, after a result of 783 million euros a year earlier.
Healthineeers last month announced the launch of a rapid antigen test kit in Europe to detect coronavirus infections, but warned that the industry may struggle to meet a surge in demand.
The development of the test and lower testing volumes for regular care wiped out nearly all profit at the diagnostics unit in the fourth quarter.
The coronavirus outbreak hit Healthineers' earnings hard in the first part of 2020, keeping full year revenues at the previous year's level of 14.5 billion euros while adjusted EBIT fell 10% to 2.23 billion euros.
But strong order growth in recent months and an expected pick up in investment activity in the U.S. are set to put the company back on a growth path next year, Healthineers said.
The outlook excludes the $16.4 billion acquisition of U.S. radiation therapy specialist Varian Medical Systems (N:VAR) announced in August, which was the first major growth move by Healthineers since it was spun off and floated in 2018 by Siemens (DE:SIEGn).
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.